California Consumer Privacy Act (CCPA) Requests
If you wish to make a request pursuant to the California Consumer Privacy Act (CCPA), please call 1-973-324-0200 or email info@alembictx.com.
Site is intended for US healthcare professionals only
If you wish to make a request pursuant to the California Consumer Privacy Act (CCPA), please call 1-973-324-0200 or email info@alembictx.com.
NUVESSA (metronidazole vaginal gel 1.3%) is an intravaginal treatment indicated for the treatment of bacterial vaginosis in females 12 years of age and older.
NUVESSA is contraindicated in:
Central and Peripheral Nervous System Effects
Convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy have been reported in patients treated with oral or intravenous metronidazole. NUVESSA should be administered with caution to patients with central nervous system diseases.
Discontinue promptly if abnormal neurologic signs development.
Carcinogenicity in Animals
Metronidazole has been shown to be carcinogenic at high doses administered orally in mice and rats. Unnecessary use of metronidazole should be avoided.
Drug/Laboratory Test Interactions
Metronidazole may interfere with certain serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed.
The most common adverse reactions (≥1%) observed in adult clinical studies were vulvovaginal candidiasis, headache, vulvovaginal pruritus, nausea, diarrhea, and dysmenorrhea.
The most common adverse reactions (≥1%) observed in pediatric clinical studies was vulvovaginal discomfort.
This is not a complete list of risks.
Please see full Prescribing Information for detailed information here.